Efficacy of the apatinib and icotinib combination therapy in the treatment of icotinib-resistant advanced lung adenocarcinoma:A case study  

作　　者：Ling-Juan Gao 

机构地区：[1]Oncology Department,The 81st Group Army Hospital of PLA,Zhangjiakou,China

出　　处：《TMR Cancer》2021年第5期4-7,共4页TMR肿瘤

摘　　要：A patient with advanced lung adenocarcinoma who was unable to tolerate chemotherapy was controlled after combined treatment with apatinib.This case provides a basis for the treatment of this disease using this method.Methods:The diagnosis of patients with lung adenocarcinoma stageⅣperiod,age,detection of EGFR mutations,line for treatment in September there progress,a large number of pleural effusions,the right lung neoplasm,cisplatin and interleukin-2 pleural perfusion chemotherapy,line again.Assessment of the EGFR gene exon 20 single did not identify a missense mutation(T790M not mutation).Patients with high collar,poor health,refused chemotherapy.Subsequently,we administered oral treatment of apatinib at 250 mg/day.Conclusion:Apatinib combined with EGFR-TKI targeted therapy is effective for lung adenocarcinoma.Moreover,adverse reactions can be controlled.

关 键 词：Apatinib EGFR-TKI Lcotinib hydrochloride tablets agedness lung adenocarcinoma 

分 类 号：R73[医药卫生—肿瘤]